Our goal: to enable the analysis of any living thing, by any person, in any environment
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be improved and workflows will become simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment.
Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in more than 50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field.
Nanopore sensing technology is fully scalable and the high-throughput, high-sample number PromethION is currently being prepared for release in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to convert complex samples such as blood, saliva or environmental samples directly onto a nanopore sensing device.
Metrichor offers analysis solutions coupled with nanopore sensing devices, with the goal of making analyses accessible to people without bioinformatics skills or even biology qualifications. Nanopore devices can be adapted for the analysis of a range of biological molecules including DNA, RNA and proteins. Supported by a broad patent portfolio, the Oxford Nanopore pipeline includes multiple generations of nanopore-based sensing technologies, including those based on both biological and solid-state nanopores.
Oxford Nanopore Technologies Ltd is a private company headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices in Cambridge (UK), New York and Boston.
The Company was founded in 2005 to develop a disruptive, electronic, single molecule sensing system based on nanopore science. The first product, MinION, is now commercially available and the Company has a rich development pipeline that includes the high-throughput, high-sample number PromethION and the mobile phone-compatible SmidgION.
The Company now has more than 300 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
Oxford Nanopore was founded on the science of Professor Hagan Bayley of the University of Oxford. In 2008 the Company created a series of collaborations with world-leading nanopore researchers at other institutions including Harvard, University of California Santa Cruz and Boston University. Further collaborations have since been added; these, in combination with in-house expertise and Intellectual Property give the company a leading position in nanopore technology.
The Company has raised £351m to date in the following fundraising rounds, and is currently well funded for the next phase of corporate development. The Company does not have traditional Venture Capital investment, instead the investor profile more closely mirrors that seen of publicly listed companies.
Seed funding was obtained in two rounds, from IP Group in 2005. In June 2006 the company raised £7.75m, and in March 2008 the company raised a further £10m. In January 2009 the Company announced an $18m (£11.9m) investment from Illumina and a separate commercialisation agreement with Illumina for the Company's exonuclease sequencing technology. In this round the Company also raised an additional £2.1m in private investment from other sources. In February 2010 Oxford Nanopore raised £17.4m from existing investors and new, undisclosed US-based investors.
In April 2011 the Company raised £25m from existing and new institutional and independent investors based in
the UK and US.
In May 2012 the Company raised £31.4m ($50.8m), the majority of which was from existing investors.
In October 2013 Oxford Nanopore raised £40m from new and existing investors in the US and Europe.
In November 2013 Oxford Nanopore performed a secondary placing and divested Illumina's stake in the
In August 2014 Oxford Nanopore raised £35m from new and existing investors in the US and Europe.
In July 2015 Oxford Nanopore raised £70m from new and existing investors in the US and Europe.
In December 2016 Oxford Nanopore raised £100m from new and existing investors worldwide.
At this stage, Oxford Nanopore is not seeking additional investment. However, if you are interested in receiving
information at the next opportunity then please use our contact form.